Provided by Tiger Fintech (Singapore) Pte. Ltd.

Eton Pharmaceuticals, Inc.

16.84
-0.4100-2.38%
Post-market: 16.840.00000.00%19:02 EDT
Volume:404.20K
Turnover:6.83M
Market Cap:451.61M
PE:-96.16
High:17.42
Open:17.11
Low:16.53
Close:17.25
Loading ...

BRIEF-Eton Pharmaceuticals Says FDA Review Expected To Take 10 Months, Potential Q1 2026 Launch

Reuters
·
28 Apr

Eton Pharmaceuticals Announces Submission of Nda for Et-600 (Desmopressin Oral Solution)

THOMSON REUTERS
·
28 Apr

Eton Pharmaceuticals Inc - FDA Review Expected to Take 10 Months, Potential Q1 2026 Launch

THOMSON REUTERS
·
28 Apr

Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)

GlobeNewswire
·
28 Apr

B.Riley Financial Remains a Buy on Eton Pharmaceuticals (ETON)

TIPRANKS
·
17 Apr

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Has Found A Path To Profitability

Simply Wall St.
·
15 Apr

BUZZ-Eton Pharma falls after co licenses rare disease drug to Spanish company

Reuters
·
01 Apr

Craig-Hallum Sticks to Their Buy Rating for Eton Pharmaceuticals (ETON)

TIPRANKS
·
01 Apr

Eton Pharmaceuticals Agrees to License International Rights for Increlex to Esteve Pharmaceuticals

MT Newswires Live
·
01 Apr

BRIEF-Eton Pharmaceuticals Inc - Esteve To Pay Eur4 Million Up Front For Increlex Rights - SEC Filing

Reuters
·
01 Apr

Eton Pharmaceuticals Inc - Esteve Has Option to Acquire International Rights to Increlex for EUR6 Million - SEC Filing

THOMSON REUTERS
·
01 Apr

BRIEF-ESTEVE Signs License & Supply Agreement With Eton Pharmaceuticals With Global Rights For Increlex, Except For USA

Reuters
·
01 Apr

Esteve: Signs License & Supply Agreement With Eton Pharmaceuticals With Global Rights for Increlex, Except for USA

THOMSON REUTERS
·
01 Apr

Eton Pharmaceuticals Out-Licenses International Rights to Increlex®

GlobeNewswire
·
01 Apr

Eton Pharmaceuticals Is Maintained at Buy by Craig-Hallum

Dow Jones
·
20 Mar

Eton Pharmaceuticals Price Target Raised to $24.00/Share From $21.00 by B. Riley Securities

Dow Jones
·
19 Mar

Eton Pharmaceuticals price target raised to $26 from $23 at Craig-Hallum

TIPRANKS
·
19 Mar

B. Riley Raises Price Target on Eton Pharmaceuticals to $24 From $21, Keeps Buy Rating

MT Newswires Live
·
19 Mar

Eton Pharmaceuticals Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.
·
19 Mar

BUZZ-Eton Pharma falls after fourth-quarter loss

Reuters
·
19 Mar